Health

Merck KGaA in Talks to Buy SpringWorks Therapeutics

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Deirdre Hipwell and Sonja Wind

February 10, 2025 at 10:16 AM EST

Updated on

February 10, 2025 at 3:18 PM EST

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare diseases drugmaker soaring.

One of SpringWorks’ drugs, Ogsiveo, is approved in the US to treat adults with connective tissue tumors. A deal could be signed in the coming weeks, according to an earlier report from Reuters that cited unidentified sources. Germany-based Merck confirmed the report in an email to Bloomberg.